These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 23014668

  • 1. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
    Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C.
    Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668
    [Abstract] [Full Text] [Related]

  • 2. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA, Espada NG, Merino RG, González TC.
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [Abstract] [Full Text] [Related]

  • 3. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, RE-NOVATE II Study Group.
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [Abstract] [Full Text] [Related]

  • 6. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
    Kwok CS, Pradhan S, Yeong JK, Loke YK.
    Chest; 2013 Aug; 144(2):593-600. PubMed ID: 23519234
    [Abstract] [Full Text] [Related]

  • 7. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.
    Int J Cardiol; 2015 Jan 20; 179():279-87. PubMed ID: 25464465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 20; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM, Crowther MA.
    Eur Heart J; 2013 Feb 20; 34(7):489-498b. PubMed ID: 23220847
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.
    Thromb Haemost; 2013 Nov 20; 110(5):987-94. PubMed ID: 23965805
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E.
    Thromb Res; 2014 Oct 20; 134(4):774-82. PubMed ID: 25037495
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan 20; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

  • 19. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):57-72. PubMed ID: 22272729
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.